Baudax Bio Valuation
| BXRXDelisted Stock | USD 0.76 0.06 7.32% |
Baudax Bio is overvalued. Baudax Bio shows a prevailing Real Value of $0.68 per share. The current price of the firm is $0.76. Our model approximates the value of Baudax Bio from analyzing the firm fundamentals such as Return On Equity of -47.04, operating margin of (27.60) %, and Shares Outstanding of 43.59 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Baudax Bio's price fluctuation is very steady at this time. Calculation of the real value of Baudax Bio is based on 3 months time horizon. Increasing Baudax Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Baudax Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Baudax Stock. However, Baudax Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.76 | Real 0.68 | Hype 0.76 | Naive 0.68 |
The intrinsic value of Baudax Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Baudax Bio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Baudax Bio helps investors to forecast how Baudax stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Baudax Bio more accurately as focusing exclusively on Baudax Bio's fundamentals will not take into account other important factors: Baudax Bio Total Value Analysis
Baudax Bio is currently projected to have valuation of 17.72 M with market capitalization of 950.33 K, debt of 7.12 M, and cash on hands of 5.65 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Baudax Bio fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
17.72 M | 950.33 K | 7.12 M | 5.65 M |
Baudax Bio Investor Information
The company has price-to-book (P/B) ratio of 0.68. Some equities with similar Price to Book (P/B) outperform the market in the long run. Baudax Bio recorded a loss per share of 94.13. The entity had not issued any dividends in recent years. The firm had 1:40 split on the 1st of December 2022. Based on the analysis of Baudax Bio's profitability, liquidity, and operating efficiency, Baudax Bio is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Baudax Bio Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Baudax Bio has an asset utilization ratio of 12.65 percent. This suggests that the Company is making $0.13 for each dollar of assets. An increasing asset utilization means that Baudax Bio is more efficient with each dollar of assets it utilizes for everyday operations.Baudax Bio Ownership Allocation
Baudax Bio holds a total of 43.59 Million outstanding shares. Almost 97.31 percent of Baudax Bio outstanding shares are held by general public with 0.01 (percent) owned by insiders and only 2.68 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Baudax Bio Profitability Analysis
The company reported the previous year's revenue of 1.27 M. Net Loss for the year was (7.15 M) with loss before overhead, payroll, taxes, and interest of (5.74 M).About Baudax Bio Valuation
Our relative valuation model uses a comparative analysis of Baudax Bio. We calculate exposure to Baudax Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Baudax Bio's related companies.Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company was incorporated in 2019 and is based in Malvern, Pennsylvania. Baudax Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 80 people.
Baudax Bio Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 331.6 K |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Baudax Stock
If you are still planning to invest in Baudax Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Baudax Bio's history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |